Literature DB >> 28285265

Neuropsychiatric syndromes of multiple sclerosis.

Ruth Murphy1, Stefani O'Donoghue2, Timothy Counihan3, Colm McDonald2, Peter A Calabresi4, Mohammed As Ahmed5, Adam Kaplin4, Brian Hallahan2.   

Abstract

Neuropsychiatric signs and symptoms occur frequently in individuals with multiple sclerosis (MS), either as the initial presenting complaint prior to a definitive neurological diagnosis or more commonly with disease progression. However, the pathogenesis of these comorbid conditions remains unclear and it remains difficult to accurately elucidate if neuropsychiatric symptoms or conditions are indicators of MS illness severity. Furthermore, both the disease process and the treatments of MS can adversely impact an individual's mental health. In this review, we discuss the common neuropsychiatric syndromes that occur in MS and describe the clinical symptoms, aetiology, neuroimaging findings and management strategies for these conditions. © Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Entities:  

Keywords:  Bipolar Disorder; Depression; Magnetic Resonance Imaging; Multiple Sclerosis; Psychosis

Mesh:

Substances:

Year:  2017        PMID: 28285265     DOI: 10.1136/jnnp-2016-315367

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  18 in total

Review 1.  Headache and Its Management in Patients With Multiple Sclerosis.

Authors:  Farhat Husain; Gabriel Pardo; Meheroz Rabadi
Journal:  Curr Treat Options Neurol       Date:  2018-03-24       Impact factor: 3.598

2.  Atypical immune response to Epstein-Barr virus in major depressive disorder.

Authors:  Lorraine Jones-Brando; Faith Dickerson; Glen Ford; Cassie Stallings; Andrea Origoni; Emily Katsafanas; Kevin Sweeney; Amalia Squire; Sunil Khushalani; Robert Yolken
Journal:  J Affect Disord       Date:  2019-11-30       Impact factor: 4.839

Review 3.  The manifestation of affective symptoms in multiple sclerosis and discussion of the currently available diagnostic assessment tools.

Authors:  Melanie Filser; Axel Buchner; Gereon Rudolf Fink; Stefan M Gold; Iris-Katharina Penner
Journal:  J Neurol       Date:  2022-09-21       Impact factor: 6.682

4.  The Impact of COVID-19 on the Lives of Individuals With Multiple Sclerosis: 1 Year Into the Pandemic.

Authors:  Sharon Lynch; Sara Baker; Suzanne Hunt; Amanda Thuringer; Yasir Jassam; Jared Bruce
Journal:  Int J MS Care       Date:  2022-05-24

5.  Network alterations underlying anxiety symptoms in early multiple sclerosis.

Authors:  Erik Ellwardt; Muthuraman Muthuraman; Gabriel Gonzalez-Escamilla; Venkata Chaitanya Chirumamilla; Felix Luessi; Stefan Bittner; Frauke Zipp; Sergiu Groppa; Vinzenz Fleischer
Journal:  J Neuroinflammation       Date:  2022-05-24       Impact factor: 9.587

Review 6.  Oxidative/Nitroxidative Stress and Multiple Sclerosis.

Authors:  Tobore Onojighofia Tobore
Journal:  J Mol Neurosci       Date:  2020-08-07       Impact factor: 3.444

Review 7.  Epidemiology and risk factors for bipolar disorder.

Authors:  Tobias A Rowland; Steven Marwaha
Journal:  Ther Adv Psychopharmacol       Date:  2018-04-26

8.  Multiple Sclerosis, Anxiety, and Depression in the United Arab Emirates: Does Social Stigma Prevent Treatment?

Authors:  Nicoline Schiess; Katherine Huether; Kathryn B Holroyd; Faisal Aziz; Essam Emam; Tarek Shahrour; Miklos Szolics; Taoufik Alsaadi
Journal:  Int J MS Care       Date:  2019 Jan-Feb

Review 9.  Insights into the Pathophysiology of Psychiatric Symptoms in Central Nervous System Disorders: Implications for Early and Differential Diagnosis.

Authors:  Giulia Menculini; Elena Chipi; Federico Paolini Paoletti; Lorenzo Gaetani; Pasquale Nigro; Simone Simoni; Andrea Mancini; Nicola Tambasco; Massimiliano Di Filippo; Alfonso Tortorella; Lucilla Parnetti
Journal:  Int J Mol Sci       Date:  2021-04-23       Impact factor: 5.923

10.  Platelet Depletion is Effective in Ameliorating Anxiety-Like Behavior and Reducing the Pro-Inflammatory Environment in the Hippocampus in Murine Experimental Autoimmune Encephalomyelitis.

Authors:  Pece Kocovski; Xiangrui Jiang; Claretta S D'Souza; Zhenjiang Li; Phuc T Dang; Xiaowei Wang; Weisan Chen; Karlheinz Peter; Matthew W Hale; Jacqueline M Orian
Journal:  J Clin Med       Date:  2019-02-01       Impact factor: 4.241

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.